Efavirenz is a non-nucleoside reverse transcriptase inhibitor used in the treatment of hiv infection. It exerts its antiretroviral effect by binding to an allosteric site on the viral reverse transcriptase enzyme. This binding stabilizes the enzyme in an inactive conformation, preventing the synthesis of new viral rna from rna template. The inhibition of reverse transcriptase reduces the replication rate of hiv within infected cells. Efavirenz is metabolized primarily by the hepatic cytochrome p450 enzyme cyp2b6, leading to variability in plasma concentrations. Its active metabolite contributes to the overall pharmacologic effect through prolonged enzyme suppression. The drug reaches therapeutic levels after oral administration with a half-life of approximately 40 to 60 hours, allowing once-daily dosing. By maintaining suppression of viral replication, Efavirenz helps preserve immune function and slows disease progression.

Efavirenz is an antiviral medication used in the treatment of hiv infection as part of antiretroviral therapy. It belongs to the class of non-nucleoside reverse transcriptase inhibitors that target the hiv enzyme reverse transcriptase. The drug binds to a specific site on reverse transcriptase, blocking its ability to convert viral rna into dna. By preventing dna synthesis, Efavirenz stops the virus from replicating and spreading in the body. This inhibition of viral replication reduces the amount of hiv circulating in the bloodstream. Efavirenz also induces certain liver enzymes, which can accelerate the metabolism of other medications. Its effect on enzyme activity is part of the reason it is often combined with other antiretrovirals to maintain efficacy. The combined suppression of hiv replication helps control infection and delays disease progression.

Efavirenz may cause dizziness and vivid dreams in some patients. Another common side effect is headache that can occur early in treatment. Some individuals experience nausea or loss of appetite while taking the medication. Fatigue is also reported by many users during the initial weeks. Rash can develop on the skin as an allergic response. Sleep disturbances, including insomnia, are frequently observed. In rare cases, mild liver enzyme elevations may be noted.

Efavirenz is an antiretroviral medication used in the treatment of hiv infection. It works by blocking the activity of the reverse transcriptase enzyme. The most frequently reported side effects are dizziness, headache, and vivid dreams. Some patients experience insomnia, fatigue, or difficulty concentrating. Skin reactions such as rash can occur but are generally mild. Gastrointestinal symptoms like nausea or loss of appetite are also noted. These effects are usually more pronounced during the initial weeks of therapy. They tend to diminish as the body adjusts to the medication.